American Society of Hematology

Press Releases

Subscribe to RSS
  • Alexis A. Thompson, MD, MPH, Begins Term as 2018 ASH President Jan 04, 2018

    Alexis A. Thompson, MD, MPH, a world-renowned expert in sickle cell disease and thalassemia, will serve as president of the American Society of Hematology for a year-long term through December 2018.

  • Editors of Blood Select Top 10 Manuscripts from 2017 Dec 22, 2017

    This year, there have been more than 1,000 manuscripts published in Blood, the Journal of the American Society of Hematology. To recognize these achievements, Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD, have selected the top 10 most outstanding manuscripts of 2017.

  • Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term Dec 12, 2017

    In four clinical trials being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers report promising results suggesting patients with blood disorders and several types of cancer will soon have significantly expanded options for treatment.

  • American Society of Hematology to Recognize Choosing Wisely Champions at 59th Annual Meeting Dec 11, 2017

    The American Society of Hematology will recognize three Choosing Wisely® Champions, practitioners working to tackle overuse of hematology tests and treatments, today at its 59th annual meeting in Atlanta.

  • People Aged 75 Years and Older Are Underrepresented in Blood Cancer Clinical Trials Dec 11, 2017

    In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

  • Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies Dec 10, 2017

    Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.

  • CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma Dec 10, 2017

    For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta spotlight the emerging role played by chimeric antigen receptor (CAR) T-cell therapies in helping individuals mount a clinical response and, in some cases, achieve durable remission.

  • Transfusion Dependence a Barrier to Quality End-of-Life Care for Some Patients with Leukemia Dec 09, 2017

    For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta. The study associates this reduced access and consequent diminished use of hospice services with a reduced quality of end-of-life care for these patients.

  • New Therapies Improve Outlook for Bleeding and Clotting Disorders Dec 09, 2017

    In three studies being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting disorders.

  • Bioengineering and Specialized Therapies Yield Results for Rare and Challenging Blood Diseases Dec 09, 2017

    In four studies being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers announce promising findings on innovative tools and therapies for hard-to-treat blood disorders including sickle cell disease, beta thalassemia, and X-linked severe combined immunodeficiency (X-SCID). The studies employ unique therapeutic approaches and advanced engineering technologies such as the gene-editing platform CRISPR/Cas9, reflecting the fruits of many years of research dedication and innovation.

1 of 34
back to top